Reduced-Dose DLI as a Strategy for EBV-Positive PTLD After HSCT
Retrospective analysis suggests reduced-dose donor lymphocyte infusion (DLI) may offer a potentially safer and more effective alternative to standard therapies for treating EBV-related PTLD following hematopoietic stem cell transplantation.